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Bone Metastatic Prostate Cancer 
An Overview of Cell Signaling, Novel Cell Culture Environment, and a Push for Cross-
Investigator Collaboration. 
 
Introduction 
Prostate cancer (CaP) continues to be the second leading causes of male cancer mortality 
in the United States despite our efforts to mitigate the cancer via better screening techniques and 
cancer management[1]. Due to clinical advancements more men are diagnosed at an earlier, 
organ-confined, stage of prostate cancer decreasing the rate of metastatic disease to 4%[2]. 
Nonetheless, metastatic disease is still a significant risk factor for those men who are not cured 
of the organ-confined disease. The treatment of recurrent prostate cancer usually consists of 
Androgen Deprivation Therapy (ADT), followed by chemotherapy and radiotherapy if the cancer 
becomes resistive and non-responding [3], [4]. Unfortunately, many bone metastasized prostate 
cancer cells become resistant to ADT and eventually leave no viable treatment options[3], [4]. 
Even more shocking is the fact that 100% of men who died of prostate cancer had bone 
metastases[4].  
In patients these bone metastases are linked to both osteoblastic and osteolytic lesions 
leading to pain, discomfort and bone fractures. Medical and research communities worked to 
develop various models to study the metastatic disease due to the lack of curative treatments and 
unknown reasons for prostate cancers affinity to bone. Currently, there are several cancer bone 
metastasis-derived orthotopic bone models, using prostate carcinoma cell lines which include: 
PC3, LAPC9, VCaP and finally PCSD1 [3], [4]. Each one of the models produces slightly 
different bone-remodeling outcomes: PC3 forms purely osteolytic lesions in intra-tibial 
xenografts, VCaP produces mixed osteoblastic/osteolytic lesions, while LAPC9 forms purely 
osteoblastic lesions but also shifts to differentiate from the original patient-derived cell lines 
based on genomic sequencing data. Finally, PCSD1 can form both osteoblastic and osteolytic 
lesions in the murine model [3], [4]. 
PCSD1 is a novel, primary prostate cancer bone metastasis-derived xenograft model 
developed in Dr. Christina Jamieson’s UCSD laboratory aimed for use as a therapeutic testing 
tool for developing novel CaP therapies [3]. A recent study showed that PCSD1 tumors were 
castration resistant, meaning they grew without the activation of the androgen receptor, in the 
bone-niche as compared to soft tissue environments[4]. Upon investigation, it was discovered 
that the WNT5A signaling pathway activates a WNT5A/BMP-6 loop, and this enables the 
proliferation, differentiation, migration, polarity and apoptosis via beta-catenin-dependent 
canonical and beta-catenin-independent non-canonical pathways[5], [6].  
Earlier studies revealed that osteoblastic differentiation mediated by BMP-2 is associated 
with increased expression of WNT5A and Ror2 [5]. Another study confirmed that WNT5A has a 
profound effect on CaP cell migration using PC3 cell line on a bone marrow stromal cell 
(BMSC) conditioned media [7].  Another finding about WNT5A is that it is expressed at higher 
levels in specific regions of bone, such as the growth plates [8]. The discovery of association 
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between WNT5A and bone-niche CaP allows room for potential novel therapeutic agents aimed 
at bone-metastatic prostate cancer. Here, we aim to delineate existing WNT5A/CaP research as 
well as demonstrate the involvement of WNT5A in the PCSD1 model.  
 As previously stated, various cell lines are created and studied in order to understand 
pathophysiology of cancer cell interactions as well as their responses to possible treatments. 
However, standard in-vitro cultured do not accurately mimic in-vivo organ systems. In order to 
mimic the structural relationships between cell-of-interest and their microenvironment various 
3D in vitro model systems have been developed [9]. The novel 3D organotypic systems, or 
organoids, can be formed from various tissue types including primary tissue and stem cells and 
are capable of mimicking in-vivo characteristics of real tissues[10]. Here, we aim to further 
evaluate the progress of organoid research as it relates to prostate cancer as well as outline 
organoid quantification techniques. 
Despite a plethora of new CaP research, even the most interactive investigators struggle 
to comprehend the full scope of the field. In order to continue studying bone-metastatic prostate 
cancer efforts have to be made in order to provide a collaborative environment between prostate 
cancer investigators, clinicians and ultimately patients. With the help of the Albert Foundation 
our lab discovered just how hard it is for patients to find out if any research is being done in 
regard to their specific cancer. It was determined that despite online searching bone metastatic 
prostate cancer there is a lack of free primary literature that is easily available to the public. 
During my time at CAMJ lab I designed and built a website that provides information about the 
bone-metastatic prostate cancer research that is being performed at UCSD by Dr. Christina 
Jamieson, as well as an online repository of other bone-metastatic prostate cancer animal models 
investigated at other institutions.   
Each section of this document will discuss the various projects that I was able to 
spearhead while at the CAMJ lab and hope that this description will ultimately prove beneficial 
to other investigators in the field of bone-metastatic prostate cancer research. 
 
WNT5A And Bone-Niche Prostate Cancer Literature Review 
The discovery of association between WNT5A and bone-niche CaP allows room for 
potential novel therapeutic agents aimed at bone-metastasized prostate cancer. My aim here is to 
further collect information about the involvement and importance of the WNT5A signaling 
pathway in prostate cancer, prostate development and its link to other cancers. A systematic 
electronic literature search was conducted to identify any publications relating to the Wnt 
signaling pathway as it relates to prostate cancer using PubMed (http://www.pubmed.gov/) and 
Cochrane Library (http://www.cochranelibrary.com/) from January 1991 to November 2016. 
Several combinations of the following search terms were used to identify pertinent publications: 
“WNT5A”, “Wnt signaling pathway”, “prostate cancer”, “malignancy”, “cancer”, and “beta 
catenin pathway”. Only peer-reviewed published articles were included in the analysis of current 
state of research of WNT5A in prostate cancer. The research was categorized into groups based 
on final conclusions including how it relates to prostate cancer, how the Wnt pathways impacts 
bone lesions and metastases, and the importance of Wnt in prostate development.  
 
Wnt Pathway and Prostate Development  
Many cancers appropriate signaling pathways normally used during organogenesis and 
development, leading to abhorrent cell multiplication. WNT5A has shown to be a key player in 
several steps of embryogenesis. Several studies further demonstrate the involvement of the Wnt 
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pathway in prostatic development. WNT5A is essential for normal prostate development where it 
regulates bud outgrowth, ductal elongation, branching, cell polarity and lumenization. WNT5A 
participates in prostatic bud patterning by restricting mouse ventral prostate development to 
prevent prostatic fistulation to the hindgut.  
 
Author and Title Journal and 
Date 
Summary and Conclusion 
Huang L, Pu Y, Hu WY, 
et al. The role of WNT5A 
in prostate gland 
development. [11] 
Dev Biol.  
2009  
In rat prostate, Wnt5A mRNA is expressed by distal mesenchyme 
during the budding stage and localizes to periductal mesenchymal 
cells with an increasing proximal-to-distal gradient during branching 
morphogenesis 
Steroids modulate prostatic Wnt5A expression during early 
development with testosterone suppressing WntA and neonatal 
estrogen increasing expression  
WntA is not essential for functional differentiation 
Wnt5A suppresses prostae Shh expression while Shh stimulates 
Wnt5A expression in a lobe-specific manner during early 
development indicating that Wnt5A participates in cross-talk with 
other members of the gene regulatory network that control prostate 
development.  
Wnt5A does not influence prostatic expression of other Wnt 
morphogens, it suppresses Wif-1 expression and can thus indirectly 
modulate Wnt signaling.  
Wnt5A is essential for normal prostate development where it 
regulates bud outgrowth, ductal elongation, branching, cell polarity 
and lumenization. 
Allgeier SHI et al.  
Wnt5A selectively 
inhibits mouse ventral 
prostate development. 
[12] 
Dev Biol.  
2008  
Wnt5A participates in prostatic bud patterning by restricting mouse 
ventral prostate development. 
In the 70% of WntA null male fetuses where the UGS was present, it 
was morphologically deformed, devoid of a pelvic urethra, and 
attached by a fistulous connection to the hindgut  
Zhang TJ1, et al. SAGE 
reveals expression of Wnt 
signalling pathway 
members during mouse 
prostate development. 
[13] 
Gene Expr 
Patterns.  
2006  
Antagonist of the Wnt pathway, secreted frizzled related protein 2 is 
highly expressed in the early prostate libraries and down regulated at 
later developmental stages.  
Only Wnt4 transcripts were detectable in the developing prostate 
Wnt pathway members are expressed in the developing prostate 
Wnt5A, the most abundantly expressed Wnt gene in the UGS 
Yamaguchi TP, Bradley 
A, McMahon AP, Jones 
S. A Wnt5A pathway 
underlies outgrowth of 
multiple structures in the 
vertebrate embryo.  [14] 
Development.  
1999 
A loss-of-function mutation of Wnt5A leads to an inability to extend 
the A-P axis due to a progressive reduction in the size of caudal 
structures 
Due to outgrowth defects observed in the developing face, ears and 
genitals, our data indicates that WntA regulates a pathway common 
to many structures whose development requires extension from the 
primary body axis 
The reduced number of proliferating cells in both the progress zone 
and the primitive streak mesoderm suggests that one function of 
WNT5A is to regulate the proliferation of progenitor cells. 
WNT5A and Prostate Cancer  
Most of the research I’ve analyzed aims to find the crucial link between Wnt pathway 
and prostatic cancer development, progression, and aggression. Although WNT5A appears to be 
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upregulated in some of the most aggressive prostate cancers, there is data to demonstrate that 
some of the most aggressive CaP shows a downregulation of WNT5A. The combination of 
research is indicative of a very complicated crosstalk of WNT5A and other receptors and ligands 
in the B-catenin pathway requiring a much more careful dissection of the signals.  
 
Author and Title Journal and 
Date 
Summary and Conclusion 
Liang X et al. 
MicroRNA-1297 
inhibits prostate cancer 
cell proliferation and 
invasion by targeting the 
AEG-1/Wnt signaling 
pathway. [15] 
Biochem 
Biophys Res 
Commun.  
2016  
miR-1297 significantly downregulated in hCaP  
Overexpression of miR-1297 inhibited CaP cell proliferation and 
invasion 
miR-1297 suppression promoted CaP cell proliferation and invasion 
Astrocyte elevated gene-1 (AEG-1 ) is a predicted target of miR-1297 
miR-1297 inhibits prostate cancer proliferation and invasion by 
targeting AEG-1, ultimately impacting the Wnt pathway 
Shu X, et al. Genetic 
variants of the Wnt 
signaling pathway as 
predictors of aggressive 
disease and reclassification 
in men with early stage 
prostate cancer on active 
surveillance.[16] 
Carcinogenesis.  
2016  
Expression of KLK3 is regulated by β-catenin allows Wnt/AR 
crosstalk 
Somatic genetic alterations in the top 6 mutated Wnt pathway genes 
were observed in 30% of prostate cancer cases: FZD3: 11%, DVL2: 
8%, PPP2CB: 8%, FZD2: 7%, FZD6: 7%, APC: 5%; cBioportal 
rs752822 and rs2735839 may assist in risk-stratifying GS 7 patients 
and predict prostate cancer reclassification 
Thiele S et al.  
WNT5A and Its 
Receptors in the Bone-
Cancer Dialogue.[17] 
J Bone Miner 
Res.  
2016  
Summary of the role of the noncanonical Wnt ligand WNT5A in the 
development and metastatic process of osteotropic cancer entities 
Tseng JC et al. CAPE 
suppresses migration 
and invasion of prostate 
cancer cells via 
activation of non-
canonical Wnt signaling. 
[18] 
Oncotarget. 
 2016  
Caffeic acid phenethyl ester (CAPE) is a main bioactive component 
of honeybee hive propolis 
CAPE treatment suppressed the migration and invasion of PC-3 and 
DU-145 CaP cells.  
CAPE treatment induced receptor ROR2 in non-canonical Wnt 
signaling pathway but suppressed abundance of β-catenin, NF-κB 
activity, PI3K-Akt signaling, and epithelial-mesenchymal transition 
(EMT).  
Overexpression or knockdown of ROR2 suppressed or enhanced cell 
migration of PC-3 cells, respectively. CAPE treatment reduced 
canonical Wnt signaling.  
Intraperitoneal injection of CAPE reduced the metastasis of PC-3 
xenografts in tail vein injection nude mice model. 
Miyamoto, et al. RNA-
Seq of single prostate 
CTCs implicates 
noncanonical Wnt 
signaling in 
antiandrogen 
resistance.[19] 
Science.  
2015  
Using CTC cells, RNA sequencing.  
Ectopic expression of WNT5A in prostate cancer cells attenuates the 
antiproliferative effect of AR inhibition  
WNT5A suppression in drug-resistant cells restores partial androgen 
sensitivity  
Thiele S, et al. WNT5A 
has anti-prostate cancer 
effects in vitro and 
reduces tumor growth in 
the skeleton in vivo.[20] 
J Bone Miner 
Res.  
2015 
In vitro, WNT5A overexpression induced CaP cell apoptosis and 
reduced proliferation and migration, WNT5A knock-down showed 
opposite effects.  
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In vivo, local tumor growth and tumor growth in the bone 
microenvironment was considerably diminished after WNT5A 
overexpression in PC3 cells.  
WNT5A exhibits antitumor effects in CaP cells  
Lee GT, et al. 
Prostate cancer bone 
metastases acquire 
resistance to androgen 
deprivation via 
WNT5A-mediated 
BMP-6 induction. [21] 
Br J Cancer.  
2014 
Bone-CaP interaction leads to castration resistance via 
WNT5A/BMP-6 loop 
In vitro co-cultures show CaP cells proliferated under an androgen-
depleted condition when incubated with bone stromal cells.  
qPCR shows induction of BMP-6 by CaP cell lines in the presence of 
bone stromal cells 
WNT5A derived from bone stromal cells ups BMP-6, upping CaP 
proliferation via a physical interaction between Smad5 and β-catenin.  
Intracellularly, WNT5A increased BMP-6 expression via protein 
kinase C/NF-κB pathway in CaP cell lines 
Zhao S, et al.  MiR-26a 
inhibits prostate cancer 
progression by 
repression of 
WNT5A.[22] 
Tumor biology  
2014 
Significant decrease of miR-26a in CaP tissues versus their normal  
Stable miR-26a inhibited cell proliferation, metastasis, and epithelial 
mesenchymal transition and induced G1 phase arrest in prostate 
cancer 
miR-26a inhibited CaP  progression via WNT5A  
Jin F, Qu X, Fan Q, 
Wang L, Tang T, et al. 
Regulation of prostate 
cancer cell migration 
toward bone marrow 
stromal cell-conditioned 
medium by WNT5A 
signaling.[7] 
Mol Med Rep.  
2013 
Expression of 22 genes associated with bone metastasis was 
measured in three PCa cell lines (LNCaP, PC3 and DU145) 
Significantly higher levels of WNT5A mRNA expression were 
identified in the PC3 cells, compared with those in LNCaP and 
DU145 cells.  
Silencing WNT5A expression with siRNA reduced the migration 
capacity of PC3 cells by 50%.  
The addition of rmWNT5A improved the migration capacity of PC3 
cells in a concentration-dependent manner.  
WNT5A promotes PC3 cell migration toward BMSC-CM 
Zheng D, et al. Role of 
WNT7B-induced 
noncanonical pathway in 
advanced prostate 
cancer.[23] 
Mol Cancer Res.  
2013 
WNT7B is necessary for the growth of CaP cells, promotes 
androgen-independent growth of CRPC cells likely through the 
activation of protein kinase C isozymes, and induces osteoblast 
differentiation in vitro through a direct cell-cell interaction 
Khaja ASS, et al.  
Emphasizing the role of 
WNT5A protein 
expression to predict 
favorable outcome after 
radical prostatectomy in 
patients with low-grade 
prostate cancer.[24] 
Cancer Med.  
2012  
Preserved high protein expression of WNT5A in prostate cancer is 
associated with longer relapse-free time after radical prostatectomy 
Patients with preserved high-WNT5A protein levels in their tumor 
cells have a lower risk of recurrence after radical prostatectomy 
compared to patients with low-WNT5A protein expression 
Kypta, R.M., et al. 
Wnt/beta-catenin 
signalling in prostate 
cancer. [25] 
 
Nat. Rev. Urol,  
2012 
Activation of the Wnt/β-catenin pathway has effects on prostate cell 
proliferation, differentiation and the epithelial–mesenchymal 
transition 
Takahashi, S et al. 
Noncanonical Wnt 
signaling mediates 
Proc Natl Acad 
Sci U S A. 2011  
CaP tumor growth was significantly potentiated by introduction of 
the AR T877A mutation  
Genetic screening of mice identified Wnt-5a as an activator.  
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androgen-dependent 
tumor growth in a mouse 
model of prostate 
cancer.[26] 
Enhanced Wnt-5a expression in malignant prostate tumors but not in 
BPH  
Noncanonical Wnt signal stimulates development of prostatic tumors 
with AR hyperfunction 
Syed Khaja AS, 
Helczynski L, Edsjo A, 
et al. Elevated level of 
WNT5A protein in 
localized prostate cancer 
tissue is associated with 
better outcome.  [27] 
PLoS One.  
2011  
Preserved overexpression of WNT5A protein in patients with 
localized prostate cancer predicts a favorable outcome after surgery 
WNT5A impairs the invasive properties of prostate cancer cells 
Patients with high expression of WNT5A protein had significantly 
better outcome in terms of time to biochemical recurrence compared 
to patients with low expression levels  
A combination of high WNT5A expression with low levels of Ki-67 
or androgen receptor expression had even better outcome compared 
to all other groups.  
WNT5A expression significantly correlated with VEGF and with Ki-
67 and androgen receptor expression 
Yamamoto H, Oue N, 
Sato A, et al. WNT5A 
signaling is involved in 
the aggressiveness of 
prostate cancer and 
expression of 
metalloproteinase. [28] 
Oncogene.  
2010  
Abnormal expression of WNT5A and beta-catenin was observed in 
27 (28%) and 49 (50%) of 98 prostate cancer cases 
Simultaneous expression of WNT5A and beta-catenin was observed 
in only five cases, suggesting their exclusive expression. 
The positive detection of WNT5A was correlated with high Gleason 
scores and biochemical relapse of prostate cancer, but that of beta-
catenin was not.  
Knockdown and overexpression of WNT5A in human prostate cancer 
cell lines reduced and stimulated, respectively, their invasion 
activities, and the invasion activity required Frizzled2 and Ror2 as 
Wnt receptors 
WNT5A activated Jun-N-terminal kinase through protein kinase D 
(PKD) and the inhibition of PKD suppressed WNT5A-dependent cell 
migration and invasion 
WNT5A induced the expression of metalloproteinase-1 through the 
recruitment of JunD to its promoter region 
Wang Q, Symes AJ, 
Kane CA, et al. A novel 
role for Wnt/Ca2þ 
signaling in actin 
cytoskeleton remodeling 
and cell motility in 
prostate cancer. [29]  
PLoS One.  
2010  
The activity of Ca2+/calmodulin dependent protein kinase (CaMKII), 
a transducer of the non-canonical Wnt/Ca2+ signaling, increased by 8 
fold in cancer cells; no change was observed in β-catenin expression, 
known to activate the canonical Wnt/β-catenin pathway 
Expression of numerous genes (e.g., CCND1, CD44) under the 
control of β-catenin transcription is down-regulated.  
Incubation of normal prostate cells with recombinant WNT5A protein 
induced actin remodeling with a regular wound edge and increased 
wound healing capacity.  
non-canonical Wnt/Ca2+ signaling via CaMKII acts as a novel 
regulator of structural plasticity and cell motility in prostate cancer 
MacDonald, B.T. et al. 
(2009) Wnt/beta-catenin 
signaling: components, 
mechanisms, and 
diseases.  [30] 
Dev Cell.  
2009  
Review article highlights some key aspects of Wnt/beta-catenin 
signaling in human diseases including congenital malformations, 
cancer, and osteoporosis, and discuss potential therapeutic 
implications. 
Wang Q, Williamson M, 
Bott S, et al. 
Hypomethylation of 
Oncogene.  
2007  
Hypomethylation of WNT5A, S100 calcium-binding protein P 
(S100P) and cysteine-rich protein 1(CRIP1) was confirmed in the 
cancer cells  
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WNT5A, CRIP1 and 
S100P in prostate 
cancer.[31] 
Bisulfite sequencing of a section of the 5' untranslated region (UTR) 
of WNT5A revealed that three CpG sites (15, 24 and 35) were 
consistently methylated (93%) in the normal cell line and normal 
tissues, but not in the prostate cancer cell line and eight primary 
prostate cancers 
Likely that an epigenetic mechanism regulates WNT5A expression in 
prostate cancer. 
Verras, M. et al. Roles 
and regulation of Wnt 
signaling and beta-
catenin in prostate 
cancer. [32] 
Cancer Lett   
2006 
Abnormal expression of Wnt ligands, receptors, inhibitors, and other 
co-regulators play important role in CaP 
Giles, R.H. et al. (2003) 
Caught up in a Wnt 
storm: Wnt signaling in 
cancer. [33] 
Biochim 
Biophys Acta. 
2003  
The Wnt signaling pathway, named for its most upstream ligands, the 
Wnts, is involved in various differentiation events during embryonic 
development and leads to tumor formation when aberrantly activated.  
 
WNT5A in other bone metastatic cancers  
The Wnt pathway is also implicated in several other cancers, specifically breast cancer 
and melanoma.  Figure 1 from paper “WNT5A and Its Receptors in the Bone-Cancer Dialogue” 
by Thiele S, et al. briefly demonstrates the common involvement of WNT5A signaling across all 
three cancers, highlighting the ligand-receptor pair’s ability to control cell migration, invasion, 
and progression.   
Breast cancer  
Cell surface receptors are a hot topic in breast cancer but remain elusive in patients with 
“triple negative” diseases. In these individuals the role of WNT5A seems to be protective. In 
fact, patients with lower WNT5A levels in tumor tissue, have an increased risk of death.  
 
Author and Title Journal and 
Date 
Summary and Conclusion 
Zhong Z, Shan M, Wang 
J, Liu T, Shi Q, Pang D. 
Decreased WNT5A 
expression is a poor 
prognostic factor in 
triple-negative breast 
cancer.[34] 
Med Sci Monit.  
2016  
WNT5A expression was evaluated in 90 TNBC specimens 
Pts with negative WNT5A expression had significantly poorer 
recurrence-free survival (RFS) than patients with positive WNT5A 
expression (P=0.008). 
Negative WNT5A protein expression might contribute to the tumor 
progression and poor prognosis of TNBC and might be a new therapy 
target in TNBC. 
Cai J, Guan H, Fang L, et 
al. MicroRNA-374a 
activates Wnt/b-catenin 
signaling to promote 
breast cancer metastasis. 
[35] 
J Clin Invest.  
2013 
In early stages, BrCa cells undergo an Wnt/β-catenin signaling is 
known to drive epithelial-mesenchymal transition (EMT) and 
metastasis 
Wnt/β-catenin signaling is hyperactivated in metastatic breast cancer 
cells that express microRNA 374a. miR-374a directly targeted and 
suppressed multiple negative regulators of the Wnt/β-catenin 
signaling cascade, including WIF1, PTEN, and WNT5A.  
miR-374a maintains constitutively activated Wnt/β-catenin signaling  
Jonsson M, Dejmek J, 
Bendahl P-O., Andersson 
T. Loss of Wnt-5a protein 
is associated with early 
Cancer Res.  
2002  
Wnt-5a gene plays a role as a tumor suppressor.  
Loss of WNT5A protein expression was significantly associated with 
higher histological grade and absence of estrogen and progesterone 
receptors.  
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relapse in invasive ductal 
breast carcinomas. [36] 
 
WNT5A expression was lost in tumors from 78% of the patients with 
recurrent disease (n = 32) compared with 35% of the recurrence-free  
Recurrence-free survival was significantly shorter in the Wnt-5a-
negative group (P < 0.001)  
 
 
Figure 1: Summary of WNT5A signaling in CaP, Breast Cancer, and Melanoma.  
 
Melanoma and beyond 
In melanoma, WNT5A has been shown to increase motility and invasion of melanoma 
cells. However, the effects of WNT5A were also shown to depend on ROR2 and ROR1. ROR1, 
when inactivated, drove cancerous melanocytes to apoptosis.  
Notably, WNT5A and ROR1 have been implicated and well studied in leukemias, 
specifically Chronic Lymphocytic Leukemia by Kipps group and Catriona Jamieson. The 
investigators developed an antibody against ROR1 that is currently in clinical trials for CLL and 
breast cancer demonstrating a real-time translation of cancer molecular signaling to 
therapeutics[37], [38].  
 
Author and Title Journal and 
Date 
Summary and Conclusion 
Choi M, Widhopf G. Pre-
clinical Specificity and 
Safety of UC-961, a First-
In-Class Monoclonal 
Clin 
Lymphoma 
Myeloma 
Leuk 2015  
Due to expression of ROR1 on the cell surface of leukemia cells in 
chronic lymphocytic leukemia (CLL), but not on normal B-cells or 
other post-partum tissues, ROR1 is a therapy candidate. UC-961 is a 
first-in-class humanized monoclonal antibody (mAb) that binds the 
extracellular domain of ROR1. This paper outlines some of the 
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Antibody Targeting 
ROR1[38]. 
preclinical studies leading to an investigation new drug (IND) 
designation, enabling clinical studies in patients with CLL. 
O’Connell MP, 
Marchbank K, et al. 
Hypoxia induces 
phenotypic plasticity and 
therapy resistance in 
melanoma via the tyrosine 
kinase receptors ROR1 
and ROR2. [39] 
Cancer 
Discov.  
2013  
The Wnt signaling pathway, can effectively guide the phenotypic 
plasticity of tumor cells, when primed to do so by a hypoxic 
microenvironment.  
Increased WNT5A signaling can give rise to a subpopulation of 
highly invasive cells that are intrinsically less sensitive to novel 
therapies for melanoma, and targeting the WNT5A/ROR2 axis could 
improve the efficacy and duration of response for patients with 
melanoma on vemurafenib. 
Grossmann AH, Yoo JH, 
Clancy J, et al. The small 
GTPase ARF6 stimulates 
b-catenin transcriptional 
activity during WNT5A-
mediated melanoma 
invasion and metastasis. 
[40] 
Sci Signal.  
2013  
In melanoma cells, WNT5A stimulated the disruption of N-cadherin 
and β-catenin complexes by activating the guanosine triphosphatase 
adenosine diphosphate ribosylation factor 6 (ARF6).  
Binding of WNT5A to the Frizzled 4-LRP6 (low-density lipoprotein 
receptor-related protein receptor complex activated ARF6, which 
liberated β-catenin from N-cadherin, thus increasing the pool of free 
β-catenin, enhancing β-catenin-mediated transcription, and 
stimulating invasion.  
O’Connell MP, Fiori JL, 
Xu M, et al. The orphan 
tyrosine kinase receptor, 
ROR2, mediates WNT5A 
signaling in metastatic 
melanoma.[41] 
 
Oncogene.  
2010  
ROR2 is expressed predominantly in metastatic melanoma, 
implicating WNT5A as a mediator of melanoma metastasis 
Increases in WNT5A cause increases in ROR2 expression, as well as 
the PKC-dependent, clathrin-mediated internalization of ROR2 
Using in vitro and in vivo metastasis assays, we show that ROR2 is 
necessary for the WNT5A-mediated metastasis of melanoma cells 
 
Conclusion  
Overall, it is evident that interest in the Wnt/Catenin pathway in prostate cancer has 
become an increasingly studied field. We know WNT5A plays a role in establishing castration 
resistance and is a ripe target for androgen insensitive PCa. Nonetheless, the novel research has 
not yet been able to establish a specific Wnt pathway target that can used therapeutically for 
prostate cancer. I believe that the difficulty lies in seemingly contradictory information regarding 
the importance of WNT5A in both prostate cancer aggressiveness and its role as a protective 
factor for recurrence.  Nonetheless, existing ROR1-specific antibody therapeutic UC-961 implies 
that molecular targeting can be useful in treatment of malignancies and should be pursued.  
 
WNT5A And PCSD1 
Initial Proposal  
Bone metastatic prostate cancer continues to be a hard-to treat problem for men all across the 
world. A newly developed xenograft PCSD1 model is a pre-clinical therapeutic development and 
testing platform to understand the mechanism of resistance to androgen deprivation therapy of 
bone metastatic prostate cancer. However, the dual osteoblastic and osteolytic nature of prostatic 
cancer tumors leads to many hypotheses regarding the effect of microenvironment on the cancer 
cell. The hypothesis I tested is that the signaling molecule WNT5A, which can be found in 
various parts of the developing bone, allows CaP cells to grow in an androgen-independent 
fashion in the bone-niche.  
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Hypotheses and Experimental Setup  
The two main hypothesis that I initially aimed to explore were as follows: 
1) There is a specific distribution of WNT5A, Ror1, and Ro2 signaling molecules on the bony 
substrate that can effect the development of the prostate cancer bone tumors.  
2) PCSD1 cells are influenced by presence of WNT5A in the bone-microenvironment.  
 
Results 
Immunohistochemical (IHC) staining of WNT5A proved to be extremely difficult to perform on 
existing xenograft model sections despite several rounds of condition optimizations and trials. 
Staining with a rabbit-anti-human WNT5A antibody showed good positive and negative control 
validity but did could not be detected on experimental sections [Fig 2-4]. Experimental 
conditions including greater concentration of primary antibody, newer sections of femurs as well 
as decreased time in overnight storage chamber were considered.  Staining appeared to be 
improved with a 1:100 concentration of antibody [Fig. 5].  
 
Figure 2. Left: Placenta, HRP stain of WNT5A, 2x. Right: Placenta, HRP stain (brown) of  1:200 WNT5A, 20x.  
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Figure 5.  
Right: 1:100 WNT5A (brown) of a PCSD1+HS5 
co-injected right leg. 10x.  
Bottom : Different areas of 1:100 WNT5A(Brown) 
of PCSD1 only injected right leg. 20x.  
Figure 3. (Left) 
Xenograft prostate 
cancer bone tumor, 
HRP stain of 1:200 
WNT5A, 2x. 
 
Figure 4. (Right) 
Xenograft prostate 
cancer bone tumor, 
HRP stain of 
WNT5A, 20x. 
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Development of in-vitro cell cultures  
 
In order to simulate more organ-like growth conditions for PCSD1 in-vitro model, we attempted 
growing PCSD1-GFP cells on HS5+HS27 stroma. The first phase of the experiment involved 
culturing irradiated human stromal cells, (HS5 and HS27) with PCSD1 on 7 and 14-day cycles. 
The cells continued to be GLF positive and were monitored with fluorescent microscopy [Fig 6, 
7]. FACs cell sort revealed only a 33% return of cancer cells. Notably, non-irradiated stromal 
cells produced a better growth environment. In order to further quantify cells with fluorescent 
microscopy, the cells were grown on sterilized glass cover-slips but cell-adhesion to glass was 
very poor. Cover slips were consequently treated with Poly-d-lysine to encourage cell adhesion. 
Cytologic PSMA staining of PCSD1 cells grown in in-vitro co-cultures was performed [Fig. 8]. 
Cells appear to be washed off cover slips as well as impacted by profound edge effect. We did 
discover that the GFP signal was only moderately quenched in this protocol. Given the poor 
results of co-culture experiment we chose to not continue the experiment.  
 
 
 
Figure 6: 20x view of PCSD1-GFP–Luciferase cells 
grown on HS5/HS27 mix. Transitional, elongated, 
cancer cells noted. 
 
Figure 7: PCSD1-GFP–Luciferase cells grown on HS5/HS27 stromal layer. 20x.   
Left: 7 day growth period. Right: 14 days of growth. Transitional cells noted. 
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Importance of Communication – the Need of a PDX model repository  
 
The following is a free-access website created for the CAMJ lab to aid in patient-derived xenograft (PDX) 
research collaboration and patient understanding regarding prostate cancer research.  
 
https://sites.google.com/ucsd.edu/pdxmodelsofprostatecancer/home  
 
The website consists of four pages outlined below: 
 
Home Page  
What is a PDX Model?  
Patient-derived xenograft (PDX) model is a type of biological model composed of patient-
derived tumor fragments that are grafted to immunocompromised mice.  
What makes PDX Models special? 
PDXs can maintain the original histology, as well as the molecular and genetic characteristics 
of the source tumor[42]. 
What is PCSD1?  
With support of the Leo and Anne Albert Charitable Trust we developed a new series of PDX 
mouse models: the PCSD series (Prostate Cancer San Diego: PCSD1, PCSD4, PCSD5, 
PCSD13, and PCSD17) of in vivo patient-derived xenograft (PDX) models which closely 
recapitulate the bone metastatic disease in patients.  
In addition, we have created and continue to grow the The Leo and Anne Albert  Bone 
Metastatic Prostate Cancer Research Center  BIOBANK.   
Is there a list of Prostate Cancer PDX Models?  
Yes, several literature reviews have been published on this matter. However, you can find a 
simplified table of the various prostate cancer PDX models that were developed and in use 
today, here. 
 
 
 
Figure 8 (Left): HS5/HS27 cells only.   (Middle): PCSD1 cells grown on HS5/HS27. (Right): PCSD1 cells only. 
Blue – DAPI nuclear stain.  Red – PSMA stain.  Green – GFP.  20x magnification.    
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Biobank  
GOAL 
To maintain and grow a BioBank of patient prostate cancer bone metastasis specimens, 
xenografts and organoids to use for genomics, basic research, pre-clinical testing of novel 
therapies and for sharing with the scientific community for translational research on bone 
metastatic prostate cancer.   
Prostate cancer bone metastases are not often surgically removed and, thus, have been 
challenging to study and to develop models to test new therapies. However, in cases in which 
the bone metastasis has caused or is about to cause a pathologic fracture, orthopaedic surgical 
repair is performed and the tumor tissue is removed. In collaboration with UCSD surgeons: 
Drs. Anna Kulidjian and Christopher Kane, and with the support of the Leo and Anne Albert 
Charitable Trust, we began collecting surgical patient prostate cancer bone metastasis 
specimens which we used to develop a new series of patient-derived xenograft (PDX) mouse 
models: the PCSD series (Prostate Cancer San Diego: PCSD1, PCSD4, PCSD5, PCSD13, and 
PCSD17) of in vivo patient-derived xenograft (PDX) models which closely recapitulate the 
bone metastatic disease in patients.  
The best characterized is the PCSD1 model which replicates a number of properties of the 
patient’s bone metastatic cancer. My group has used whole exome sequencing, genome-wide 
CNV analysis, single cell RNASeq, microarray expression profiling, RT-PCR, qPCR, FACS, 
immunohistochemistry and microCT scanning to show that our PDX model closely reproduced 
bone metastatic disease in prostate cancer patients. We have shown that the bone 
microenvironment specifically promotes resistance to androgen deprivation therapy with either 
bicalutamide or enzalutamide treatment. 
We use our PDX models to test novel therapies, including CART immunotherapies, to 
overcome therapy resistance of bone metastatic prostate cancer. 
The PCSD BIOBANK consists of the surgical patient specimens, the PCSD series of PDX and 
patient derived organoids (PDOs) models of prostate cancer bone metastasis already generated 
from the biospecimens that we have collected and new patient specimens that we continue to 
collect using the UCSD Moores Cancer Center Biorepository.  Thus far, we have 20 surgical 
specimens of prostate cancer bone metastases, PCSD1-20, numbered in the chronological order 
in which they were received. Full urologic and orthopaedic donor patient clinical information 
is available from a de-identifed database. Specimens from five patients who spanned the 
spectrum of different treatment stages have established serially transplantable xenografts: 
PCSD1, PCSD4, PCSD5, PCSD13 and PCSD17. Matched patient whole blood, sera, and urine 
are also available along with FFPE prostatectomy tissue on the patients who had this procedure 
in prior treatment. 
 
CAMJ Lab 
Who we are 
We are a small but fearless team of researchers commanded by Dr. Christina Jamieson at UC 
San Diego. 
 
Our Focus 
Dr. Jamieson's research is focused on elucidating mechanisms of therapy resistance in bone 
metastatic urologic cancers using patient-derived xenograft (PDX) models and 3D in vitro 
models. She is applying her expertise in genome-wide analyses of prostate cancer tumors and 
primary patient-derived tumor models to translate next generation genomics on prostate cancers 
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into practical applications and novel therapies that will improve and, she hopes, eventually 
transform patient care. 
 
 
PDX Models 
 
Figure 9:  
Screenshot of PDX 
Models tab 
showing the bone-
metastatic prostate 
cancer cell lines 
highlighted in 
purple.  
 
 
 
 
 
 
 
 
 
Prostate Cancer Organoids 
Background 
Despite the prevalence of prostate cancer research, in vitro studies have been hard to establish 
and even harder to equate to in-vivo conditions until recent years. With development of 
organoid-based cultures we are getting closer to in-vivo-like conditions within the comfort of an 
incubated petri-dish. Three-dimensional organoid cultures have proven to be of value in 
increasing our understanding of the biology of disease and offer the potential of regenerative and 
genetic therapies. Wang et al  summarized the use of organoids in urological research in 2017 
however, several questions remain: First - how are PCa organoid cultures defined, validated and 
studied? And second – is there a validated pathway to testing biopharmaceuticals on in-vitro 
organoid cultures? The goal of this literature review is to further define organoid research as it 
relates to prostate cancer.  
Methods 
A systemic electronic literature search was conducted to identify any publications relating to the 
use of Organoid cell culture as it relates to prostate cancer using PubMed 
(http://www.pubmed.gov/) and Cochrane Library (http://www.cochranelibrary.com/) from 
January 1997 to December 2017. Several combinations of the following search terms were used 
to identify pertinent publications:  ‘Prostate Spheroids”, “Organoid”, “3D Cell Culture”, 
“prostate cancer”, and “malignancy”. Only peer-reviewed published articles were included in the 
analysis of current state of research pertaining to prostate cancer organoids. The research was 
categorized into groups based on final conclusions including how the development of organoid 
cell culture impacts in vitro cancer research, how the authors quantified the research and what 
conditions were used to maintain cultures. Exclusion criteria: papers not peer reviewed.  
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A brief history of organoids:  
   
1997 The term “organoid” used to describe 3-dimensional prostate cancer cell culture. 
The 3D growth model was composed of CaP+ bone stroma (in collagen gel or 
microgravity-simulated growth conditions) by Chung et al [43]. 
2001 Lang et al. cultures 3D human prostate tissue in Matrigel[44].  
 Rhee et al. shows effect of estrogen on 3D in-vitro culture by measuring PSA 
expression[45]. 
2005 Festuccia et al. uses a 3D organoid model to draw conclusions about prostatic neoplasia 
vs cancer. Tests the effect of DHT on cell culture by cell counting[46].  
2007 Li et al. demonstrates self-renewal and multilineage differentiation from single adult 
prostate stem/progenitor cells in a specific in vitro microenvironment[47]. 
 Tyson et al. demonstrates that organoid culture conditions can be varied, records effect of 
extracellular calcium on organoid morphology[48]. 
2013 Zhang et al. uses specifically defined organoid conditions in order to test importance of 
CECAM gene group in CaP[49]. 
2014 Karthaus et al. defines growth conditions to produce organoids that are genetically 
stable, reconstitute prostate glands in recombination assays, and can be 
experimentally manipulated[50]. 
 Gao et al.  performs  whole exome sequencing to show mutations in FOXA1 and PIK3R1, 
as well as of DNA repair and chromatin modifier pathways linked advanced disease[51].  
 Chua et al masters single cell organoid development [52]. 
2015 Gao et al. and Vela et al. publish reviews on organoid development[53], [54]. 
 Robinson et al. recognizes the need for complex 3D imaging techniques, implements 
Markov fields (mathematics) to help cell tissue culture studies [55]. 
 Harma et al. uses 3D organoid cultures to study AKT-inhibitors in prostate cancer [56]. 
 Agarwal et al. demonstrates two types of luminal progenitor cells in CaP[57].  
 Lee et al. uses organoid cultures to further study the origin of CaP.[58]  
2016 Drost et al. further describes the culture protocol that allows the growth of both the 
luminal and basal prostatic epithelial lineages, as well as the growth of advanced 
prostate cancers[59].  
 Park et al. implies that distinct subtypes of prostate cancer may arise from luminal and 
basal epithelial cell types subjected to the same oncogenic insults. Provides a platform for 
the functional evaluation of oncogenes in basal and luminal epithelial populations of the 
human prostate [60]. 
2017 Zhang et al continues to hunt down the “Cell of origin” for CaP by studying Normal 
Human Prostate cells (NHPs)[61].  
 Unno et al.  Prostate cancer organoids provide a useful pre-clinical model for the 
evaluation of new candidate cancer genes, cancer disparities, and potentially for testing of 
novel therapeutic agents[62]. 
 Blattner et al. and Shoag et al. study SPOP mutations in mouse organoids to link them to 
increased proliferation[63], [64].  
 Pan et al. tests gambonic acid on prostate organoids in hopes of validating its effects on 
in-vivo CaP[65].  
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Growth Conditions for Organoid culture 
Although various methodologies have been described since 1997, the most cited method was 
described by Karthaus et al and had the following requirements.  
For murine cells, “[We] embedded dissociated cells of wild-type murine prostate epithelium in 
Matrigel and added ‘‘generic’’ organoid medium containing the growth factors EGF, Noggin, 
and R-spondin1 (ENR). We also included the Alk3/4/5 inhibitor A83-01 to inhibit TGF-b 
pathway signaling to prevent a proliferative block in prostate cells.” [50]. 
Human prostate organoid cultures required additional growth factors including: Ffibroblast 
growth factor-10 (FGF10), FGF2, prostaglandin E2 (PGE2), nicotinamide and the p38 inhibitor 
SB202190.   
Most recently, Ma et al. demonstrated a very precise protocol for organoid cultures of LnCAP 
and C4-2B cell lines with Matrigel and organoid medium containing 50× diluted B27, 1.25 mM 
N-acetyl-L- cysteine, 5 ng/ml EGF, 100 ng/ml Noggin, 500 ng/ml recombinant R-spondin 1, 500 
nM A83-01, 10 ng/ml FGF10, 5 ng/ml FGF2, 1 µM PGE2, 10 mM nicotinamide, 10 µM 
SB202190, 1 nM DHT, and 10 µM Y-27632 dihydrochloride [66].  
Present “Future” Directions 
Now that organoid growth conditions have been well established and studied for both murine and 
human prostate cancer cells, several questions remain regarding the quantification of organoid-
bound-cells. How do we confirm prostatic lineage withing organoids? How can we study 
organoid responses to therapeutics? A wide array of quantification and qualification techniques 
has been used across many research groups including: qrtPCR, rtPCR, Western Blotting, Whole 
Exome Sequencing, immunohistochemistry (IHC), immunofluorescence (IF), flow cytometry, or 
via size measurement obtained via light microscopy.  
Properties of cells and organoids that were often quantified were organoid diameter at various 
timepoints, organoid morphology as being hollow vs filled, and organoid edges as being smooth 
or irregular. Some of markers that were studies across many laboratories included PSA, PSMA, 
Cytokeratins (CK4, CK14, CK8, CK18) to distinguish basal vs luminal cell types, p63, CD44, 
CD49. The table below demonstrates the various experimental conditions and their check-points 
for prostate organoid research.   
 
Author Experimental Conditions, checks, and outcomes 
Lang et al. 
2001[44] 
- Human primary cultures in Matrigel 
- Dihydrotestosterone (DHT) and Estrogen increased spheroid-forming efficiency as 
measured by number of spheroids per high-power field.  
Rhee et al. 
2001[45] 
- Prostate cancer cells (LNCaP) cultured in a three-dimensional rotating-wall vessel 
- Assessed effect of DHT and 17-beta-estradiol (17-13-E2) at various concentrations (1-
100nM) on cell growth (calculated via cell counts) and PSA secretion (measured in ng/mL) 
- both DHT and 17-13-E2 lead to increase in cell counts of LNCaPs and associated cells  
Festuccia et 
al. 2005 
[46] 
- Showed the differential expression of epithelial and prostatic markers in 30 CaP, 6 high 
grade prostate intraepithelial neoplasia (PIN) and 6 BPH-derived primary cell cultures 
- Growth response study of DHT (0.01-10uM) on “organoids” based on cell number.  
Li et al 
2007[47] 
-  Murine prostate stem cells plated in vitro in laminin containing Matrigel medium form 
clonogenic spheroid structures or “prostate spheres”.   
- Addition of DHT to culture medium drives differentiation to a luminal cell-like phenotype 
as validated via qRTPCR for K5 and K8 and AR.  
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Beltran et 
al. 2011[67] 
- Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that 
most commonly evolves from preexisting prostate adenocarcinoma (PCA).  
- Used next-generation RNA sequencing and oligonucleotide arrays, profiled 7 NEPC, 30 
PCA, and 5 benign prostate tissue (BEN) samples and validated findings in tumors from a 
large cohort of patients (37 with NEPC, 169 with PCA, and 22 with BEN) using 
immunohistochemistry and FISH.  
- Enhanced sensitivity of NEPC (and MYCN overexpressing PCA) to Aurora kinase 
inhibitor (PHA-739358 ) both in vitro and in vivo , with complete suppression of 
neuroendocrine marker expression following treatment assessed with immunoblotting.  
Zhang et al. 
2013 [49] 
- Prostate cancer cells were grown on Matrigel  
- Inhibition of CEACAM1 with antibodies inhibited tubule formation by over 50% while the 
remaining tubules were stunted.  
- Inhibition of CEACAM20 with antisense oligonucleotides inhibited tubule formation and 
stunted the growth of acini.  
- For inhibition assays, soluble-CEACAM1 or antibodies were added to medium. Colonies 
with or without tubule formation were counted with an inverted light microscope. 
Measured: colony numbers, colonies with tubules and mean fluorescence intensity.  
Gao et al. 
2014 [51] 
- Developed a long-term organoid culture of prostate cancer from biopsy specimens and 
circulating tumor cells that recapitulate molecular diversity of CaP subtypes and retained the 
histology, grade and genomic alterations properties of the original cancer  
- Whole exome sequencing shows a low mutational burden, consistent with genomics 
studies, but with mutations in FOXA1 and PIK3R1, as well as of DNA repair and chromatin 
modifier pathways. 
- Cell viability assays included treatment of 5000 organoids with DHT, Enzalutamide, 
everolimus. Cells were counted using a CellTiter-Glo Luminescent Cell Viability Assay. 
Chua et al. 
2014[52] 
- Organoids generated from CARNs (castration-resistant Nkx3.1-expressing cells) or normal 
prostate epithelia within Matrigel exhibit tissue architecture containing luminal and basal 
cells, undergo long-term expansion in culture and exhibit functional androgen receptor 
signaling  
- Analyzed effect of DHT, dimethylsulphoxide (DMSO) [no effect], and Enazlutamide 
[minimal effect on organoid formation]. Treatment with enzalutamide and MK-8669 
inhibited organoid formation as observed with light microscopy and qRT-PCR.  
Karthaus et 
al. 2014 
[50] 
-Established organoids from mice prostate and human postate 
- measured by dose-dependent induction of PSA mRNA by DHT and reduced expres- sion 
of NKX3.1 and PSA upon DHT withdrawal via qRT-PCR 
Harma et al 
2015 [56] 
- Testing of betulins and abietane derivatives organotypic model system of advanced, 
castration-resistant prostate cancers. 
- Preliminary screen of 93 compounds done in 2D cultures with Epithelial cells, EP156T and 
LNCaP and PC-3. From those, 25 betulin derivatives were tested with 3D cultures and effect 
on cell cycle progression, mitosis, proliferation and unspecific cytotoxicity, cell motility and 
tumor cell invasion monitored.  
- Testing was done via qRT-PCR, WB, organoid size and organoid complexity studied.  
Akerfelt et 
al 2015 [68] 
-Developed a platform of microtissues from prostate cancer cells, combined with cancer 
associated fibroblasts (CAFs)  
- Chemical perturbation of selected proteins that are associated with tumorigenesis; 
wingless-type MMTV integration site family (WNT), β-catenin signaling, and γ-secretase 
protein complex (Notch), FAK, AKT kinase (AKT), phosphoinositide-3-Kinase (PI3K) and 
mammalian target of rapamycin (mTOR) and GMCSF. Results were monitored by cell 
counting/organoid counting and motion detection [Fig 10] 
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-Showed that focal adhesion kinase (FAK) inhibitors specifically blocked tumor growth and 
invasion concurrently with fibroblast spreading and motility.   
Kwon et al 
2015[69] 
- Sca-1 (stem cell antigen-1) identifies a small population of murine prostate luminal cells 
that reside in the proximal prostatic ducts adjacent to the urethra.  
- In the in vitro prostate organoid assay, a small fraction of the Sca-11 luminal cells are 
capable of generating budding organoids that are morphologically distinct from those 
derived from other cell lineages. 
- Enzalutamide treatment did not impact formation of organoids as verified by cell counting.   
Blattner et 
al 2017 [63] 
- Using these models and human prostate cancer samples, showed that SPOP mutation 
activates both PI3K/mTOR and androgen receptor signaling, uncoupling the normal 
negative feedback between these two pathways. 
- To test SPOP mutation, the researchers checked the percentage of mutation-positive 
organoids, relative protein expression and PTEN PAKT staining. 
Unno, et al 
2017[62] 
-used human prostate cancer as a model, to assess feasibility of engineering defined genetic 
alterations in well-known cancer driver genes to transform benign prostate epithelial 
organoids derived from African American men.   
- Benign human prostate organoids  transduced with lentiviruses expressing MYC, shPTEN, 
shTP53 and AR, to mimic prostate cancer development.  
- Organoids expressing MYC, shPTEN, shTP53 and AR (denoted MPPA); MYC, shPTEN 
and shTP53 (MPP); or MYC (M) were significantly larger, had higher proliferation rates and 
demonstrated pathologically transformed morphology compared to organoids transduced 
with control lentivirus.  
- Alterations in MYC, PTEN and TP53 also affected the rate of organoid basal-to-luminal 
differentiation in vitro as checked by microscopy, IHC, and qRTPCR, and viability 
measured with CellTiter. 
Pan et al 
2017[65] 
-Explored effect of gambogic acid (GA) on the growth and cell death of castrate resistant 
CaP with PTEN- and p53- to show that GA reduced cells viability in both cell types 
- LAPC and benign prostate cancer cells treated with GA(50-150nM) for 24 and 48hrs then 
cell viability was determined by cell proliferation assay. Cells were also counted via 
microscopy, FACS, WB and cell titer glo assay performed. 
Dai et al. 
2017 [70] 
- Bromodomain inhibitors (JQ1 and I-BET) show good results in early trials outcomes in 
early clinical trials.  
- Pathologically, prostate cancer–associated SPOP mutants fail to interact and promote the 
degradation of BET proteins, leading to increased levels in SPOP-mutant prostate cancer.  
- prostate cancer cell lines and organoids derived from individuals harboring SPOP 
mutations are more resistant to BET-inhibitor-induced cell growth arrest and apoptosis 
studied via cell proliferation assays.   
Ma et al 
2017[66] 
-Reconfirm that LNCaP and C4-2B cells are able to form organoids under the 
defined organoid culture conditions (Matrigel) 
-Tested the response of organoids vs 2D cultured to interleukin-17A treatment, showing that 
treatment differently from the cells in the monolayer culture. The mRNA levels were 
analyzed by qRT-PCR.  
 
Conclusion 
It appears that several research groups are using the prostate cancer organoid models to test 
therapeutics as well as explore prostate cancer genomics and origins. Despite having a well 
outlined protocol of cell growth media the protocol for ascertaining organoid responses to testing 
conditions remains variable with qRT-PCR of known cell bio markers being the most frequently 
utilized testing parameter. It is evident that 2D cultures differ from 3D cultures in their relative 
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expression of mRNA [64] elucidating the fact that culture conditions have to be controlled prior 
to analyzing therapeutics. However, methodology demonstrated by Gao, Clevers, and Sawyers 
allow for recapitulation of histological and morphological traits of cancers leading us to believe 
they are more accurate than traditional 2D cell cultures for testing therapies.  
 
 
 
Figure 10. Example of the various physical parameters of organoids studied by Akerfelt in order to 
categorize differences in organoids.  
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